Research peptide catalog: how families, sizes and documentation status are organised

What a catalog is a list of

A catalog looks like a list of products and is better read as a list of claims. Each entry claims that a substance exists in stock, in a stated form, at a stated quantity, with stated documentation, at a price. A laboratory buyer reading the catalog is reading those claims, and the structure of the catalog decides how easy they are to check. This page explains the structure a research peptide catalog should have, what each level of it means, and where the claims live so a buyer can find them.

The structure matters more than it looks because the category is organised loosely. Suppliers list the same substance under different names, mix salt forms without saying so, show sizes without the unit cost that makes them comparable, and list sequences they do not hold beside ones they do. A catalog built properly removes each of those problems by putting the right fact at the right level, and the levels are the subject of the next section.

Families, forms and SKUs

The top level is the family: one substance, in one form. BPC-157 as an acetate salt is a family. The same peptide as a trifluoroacetate salt would be a different family, because it is a different substance with a different mass per milligram, and a catalog that lists both under one name has hidden a difference that changes the arithmetic on the bench. The family carries the identity fields: the sequence in standard notation, the CAS number, the molecular formula and weight, the salt form, and the safety data sheet, which is written for the substance and applies to every lot of it.

Beneath the family sit the SKUs, one per size. A 5 mg vial and a 10 mg vial of the same family are the same substance at different fills, and each is its own stock-keeping unit with its own price, its own labelled mass, and its own stock status. What the labelled mass means, fill weight or peptide content, is a family-level fact, because it follows from how the supplier fills; it should be stated once and apply to every size. The net content guide explains why that convention changes what a laboratory actually receives.

Beneath the SKU, and cutting across it, is the lot. A lot is what was made or filled together and tested together, and one lot may fill several sizes while one size may draw on several lots over time. The lot is where the certificate lives. A catalog that names the lot currently shipping for each SKU, and links its certificate, has connected the identity claims at the family level to the evidence at the lot level, and that connection is the whole reason the structure exists.

The three levels also answer three different questions, which is why they should not be collapsed into one page of fields. What is it: the family. How much of it, at what price: the SKU. What was this particular material found to be: the lot. A catalog that answers each at the level it belongs to can be read in the order a buyer asks them.

Aliases, and why they belong on the record

Research peptides accumulate names. A sequence may have a systematic name, a code from the laboratory that first described it, a trade name from the first supplier to sell it, and several spellings of each. TB-500 and the thymosin beta-4 fragment it refers to; CJC-1295 with and without its drug affinity complex; MOTS-c with and without the species qualifier; Epithalon, Epitalon and the tetrapeptide sequence behind both. A buyer searching by one name and a catalog listing by another will miss each other, and worse, a buyer may find a different substance under a similar name.

A catalog handles this by listing aliases on the family record, so that every name the substance goes by resolves to the one entry, and by stating which name is canonical. The CAS number does the same job in a form that cannot be misspelled, which is why the CAS number guide treats it as the anchor for the rest. Where two substances share a name root, the record should say which one this is and name the other, because the confusion is predictable and a record that pre-empts it has saved a buyer an error.

Aliases also carry a compliance meaning. Some names in circulation are trade names for products marketed for uses a research supplier does not sell for. A research catalog lists the substance by its chemical identity and may note the alias so a buyer can find it; it does not adopt the marketing name as the product's name, and it does not describe what the marketed product claims to do.

Size ladders and the unit cost

Most families are offered in several sizes, and the sizes form a ladder in which larger fills cost less per milligram. That is ordinary volume pricing and it is worth showing explicitly, because a buyer comparing a 5 mg and a 10 mg vial is really comparing cost per milligram, and a catalog that prints only the vial price has left the comparison to mental arithmetic.

The figures are deliberately not real numbers, because the point is the columns, not the prices. A catalog that computes cost per milligram and the saving against the smallest size, and shows it on the record, has done the comparison honestly. The cost-per-milligram tool does the same arithmetic for any two listings, from any supplier, including the correction for net content that the labelled mass hides.

Two cautions. Cost per milligram should be compared on the same labelled-mass convention, since a supplier labelling peptide content will look more expensive per milligram than one labelling fill weight while delivering more peptide. And volume pricing that only appears at quantities no laboratory would order is a marketing device rather than a ladder; the bulk supply guide covers where genuine volume pricing begins.

Documentation status, family by family

The single most useful thing a catalog can show at a glance is where each family stands on documentation, and almost none do. A status per family, derived from the lot currently shipping, answers the buyer's first question before the record is opened.

The honest statuses are few. A lot with a certificate from a named laboratory, linked and verifiable, is documented. A lot whose certificate is on file but not yet linked, or from a laboratory not yet verified, is pending, and the record should say which fields are pending. A lot with no certificate at all is undocumented, and a catalog that sells it should say so rather than leave the field blank in a way that reads as complete. What a catalog must not do is show a status it cannot support: a badge reading tested on every family, derived from nothing, is the category's most common lie and its easiest to spot, because it never changes.

Status is derived, not typed. A supplier that computes it from its documentation records cannot overstate it, because the number of documented lots is whatever the records hold. A supplier that types it can, and does. The Verify a COA page states the count of documented lots here from the same records the product pages draw on, so the two cannot disagree.

Stock status and the ledger behind it

A stock status is a claim about a count, and a catalog should be able to say where the count comes from. The honest derivation is short. Start from confirmed purchase orders that have actually been received, in units: so many boxes of so many vials. Subtract units shipped as orders go out. Subtract any vials held back from sale, such as one per lot retained for the supplier's own reference. What remains is the number in stock, and it changes only when one of those three inputs does.

Read that way, several familiar displays reveal themselves. A count that never moves is not derived from shipments. A low-stock warning on every product is not derived from anything. In stock for a family whose purchase order has been placed but not delivered is a promise about a delivery, and a promise is not inventory; the honest status for that family is not listed, or listed with a waitlist rather than a buy button. And a family that has sold out should say so and offer a waitlist, because a backorder disguised as available stock is a dispatch cutoff the supplier already knows it will miss.

The ledger has a second use. When a buyer asks which lot an order shipped from, or how many units of a lot were sold, the same records answer. A supplier that derives its stock status from a real ledger has forward traceability as a by-product, since the ledger already knows what left and when. A supplier that types its stock status has neither, and the two failures usually arrive together. The batch traceability guide sets out what those records have to reach; the stock status is simply the first place a buyer can see whether they exist.

Blends, diluents and other things in the list

A catalog holds more than single peptides, and the other entries follow the same rules with one or two adjustments.

A blend is two or more peptides supplied together in one vial. It is a mixture, not a substance, and its record should carry the identity fields of each component, the proportion, and the salt form of each, with no single CAS number claimed for the mixture because none exists. The certificate for a blend lot should report identity and purity for each component separately, since a chromatogram of a blend has two main peaks and a mass spectrum has two masses, and a single purity figure for a blend is a number without a clear meaning.

A diluent, such as bacteriostatic water, is a catalog item because a laboratory preparing research solutions needs one, and it has its own documentation: composition, preservative concentration, and the container's fill volume. It is measured in millilitres, not milligrams, and has no peptide content, so the size ladder and the net content logic do not apply to it. A catalog that lists it beside the peptides should keep its record on its own terms rather than forcing it into a peptide's fields.

What a catalog should not contain is anything it does not hold. A family without a confirmed purchase order behind it is not inventory, and listing it as though it were is a claim of stock the supplier cannot meet. The honest handling is to keep such families off the indexable catalog entirely until the order is confirmed, and that is how this catalog is built: families pending stock render only on a review copy of the site, never on the live one.

Reading a catalog quickly

1. Find the family, by any name. If the alias you know does not resolve, the catalog has a naming gap; if it resolves to a different substance, it has a worse one.
2. Read the family-level facts. Sequence, CAS number, formula, weight, salt form, labelled-mass convention, safety data sheet.
3. Read the documentation status and open the lot. Named lot, linked certificate, named laboratory, verification route. The certificate overview covers what the document proves.
4. Read the size ladder as cost per milligram. On the same convention, corrected for net content where the certificate reports it.
5. Check the stock status is derived. A count that never moves is a graphic.

Every family in the LabFirst catalog is meant to pass that reading from its own record: one substance in one stated form per family, aliases listed, the size ladder shown with unit cost, the shipping lot named with its certificate and verification route where the report has landed, documentation status derived from the records, and nothing listed for sale without a confirmed order behind it. The listing guide covers the anatomy of a single record in more depth.

A catalog lists substances and what is known about each lot of them. It lists nothing about what any substance is for. FOR LABORATORY AND IN-VITRO RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL CONSUMPTION. Research peptides are supplied to laboratories, and the structure described on this page exists so a laboratory can find, compare and verify what it is buying, and for no other purpose.

What is Epithalon studied for?

Published research on Epithalon investigates the areas below — which is a different question from what Epithalon will do for anyone, a claim about a living system that nothing on this site is sold for.

What it is. A man-made peptide of four building blocks.

What the research looks at. It appears in a limited set of animal and cell studies. The evidence behind it is far thinner than the volume of commercial writing about it suggests.

How it is thought to work. Not established. The published record is small, and much of the original work comes from a narrow group of researchers, which is a real limit when reading it.

What is not established. No approved product, no official standard, and no settled mechanism. Claims made for this compound in vendor copy routinely go well past what the sources they cite actually say.

The full record, including the certificate for the lot in stock, is on the Epithalon product page.

Common questions

Sources

• CAS, CAS REGISTRY: what is a CAS Registry Number. The identifier that anchors a family record and resolves aliases to one substance.
• FDA / ICH Q6B, Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. The specification framework that separates family-level identity from lot-level results.
• 21 CFR 211.84, Testing and approval or rejection of components, drug product containers, and closures. Why documentation status must rest on a validated record rather than a typed badge.
• OSHA, 29 CFR 1910.1200 Appendix D, Safety Data Sheets (Mandatory). Why the safety data sheet is a family-level document and what its composition section must name, including for blends.
• IUPAC-IUBMB Joint Commission on Biochemical Nomenclature, Nomenclature and Symbolism for Amino Acids and Peptides. The notation the family record's sequence line follows, so aliases can be checked against one canonical structure.
• FDA, Recalls: Background and Definitions. Why the lot, not the SKU, is the unit a certificate and any future containment attach to.